Patents by Inventor James A. Matson

James A. Matson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9424371
    Abstract: A method, system, apparatus, and computer program product provide the ability to augment an as-built model. A CAD drawing of a project as well as a digital representation of a physical implementation of the project are obtained. A relationship that maps the digital representation to the CAD drawing is defined/established. A component of the digital representation is identified based on the relationship (e.g., and a database/catalog). Information about the identified component is transmitted to and displayed on a computer (e.g., a mobile device).
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: August 23, 2016
    Assignee: Autodesk, Inc.
    Inventors: Robert Matthew Shear, James Matson Awe, Brian A. Pene, Eddy Kuo, Keshaba Chandra Sahoo
  • Publication number: 20120116728
    Abstract: A method, system, apparatus, and computer program product provide the ability to augment an as-built model. A CAD drawing of a project as well as a digital representation of a physical implementation of the project are obtained. A relationship that maps the digital representation to the CAD drawing is defined/established. A component of the digital representation is identified based on the relationship (e.g., and a database/catalog). Information about the identified component is transmitted to and displayed on a computer (e.g., a mobile device).
    Type: Application
    Filed: November 7, 2011
    Publication date: May 10, 2012
    Applicant: AUTODESK, INC.
    Inventors: Robert Matthew Shear, James Matson Awe, Brian A. Pene, Eddy Kuo, Keshaba Chandra Sahoo
  • Publication number: 20070184533
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Application
    Filed: April 6, 2007
    Publication date: August 9, 2007
    Inventors: Wenying Li, James Matson, Xiaohua Huang, Kin Lam, Grace McClure
  • Patent number: 7244594
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Grant
    Filed: March 23, 2004
    Date of Patent: July 17, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Publication number: 20060163138
    Abstract: The present invention relates to a method and system for using a hemofilter to treat IMRD, hepatic failure, exogenous intoxication and other conditions associated with toxins in a patient's blood. One treatment includes the use of a very large pore hemofilter to remove target complex molecules and/or target molecules from a patient's blood and to infuse a replacement fluid into the patient's blood to maintain a prescribed albumin concentration in the patient's blood.
    Type: Application
    Filed: March 23, 2006
    Publication date: July 27, 2006
    Inventors: David Radunsky, James Matson, Patrice Lee
  • Publication number: 20050029193
    Abstract: A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal to create a filtered blood stream and an ultrafiltrate stream. The adsorptive device may include one or more adsorbent materials and may be used to adsorb inflammatory mediators from the ultrafiltrate stream received from the hemofilter to create a post adsorption ultrafiltrate stream. The post adsorption ultrafiltrate stream may be selectively combined with the filtered blood stream and together with the filtered blood stream may be returned to the mammal.
    Type: Application
    Filed: May 12, 2004
    Publication date: February 10, 2005
    Inventor: James Matson
  • Publication number: 20040176429
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Application
    Filed: March 23, 2004
    Publication date: September 9, 2004
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Patent number: 6780620
    Abstract: A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: August 24, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wenying Li, James A. Matson, Xiaohua Huang, Kin Sing Lam, Grace A. McClure
  • Patent number: 6509906
    Abstract: A method, apparatus, and article of manufacture for enabling the creation of authorable, dynamic software objects. An apparatus made in accordance with the present invention comprises a computer and an attached monitor, stream means, display property means, display representation means, and display configuration means. The stream means is performed by the computer and accepts at least one graphic primitive into the software object. The display property means is performed by the computer and stores at least one quality associated with each graphic primitive in the software object. The display representation means is performed by the computer and graphically represents a selected set of display properties of the software object. The display configuration means is performed by the computer and selectively displays one of the sets of graphical representations of the software object on the monitor of the computer.
    Type: Grant
    Filed: April 29, 1999
    Date of Patent: January 21, 2003
    Assignee: Autodesk, Inc.
    Inventors: James Matson Awe, Marc Wagner Schindewolf, Chad Steven Ames
  • Patent number: 5643871
    Abstract: The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.
    Type: Grant
    Filed: November 23, 1993
    Date of Patent: July 1, 1997
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Thomas T. Dabrah, James A. Matson, Kin Sing Lam, Donald R. Gustavson, Grace A. Hesler, Ronald L. Berry
  • Patent number: 5468849
    Abstract: Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.
    Type: Grant
    Filed: March 21, 1994
    Date of Patent: November 21, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Patent number: 5344823
    Abstract: A new antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: September 6, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Leonard A. McDonald, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Patent number: 5326754
    Abstract: An antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: July 5, 1994
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Kin S. Lam, Leonard A. McDonald, Jacqueline Mattei, Salvatore Forenza, James A. Matson
  • Patent number: 5158938
    Abstract: Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.
    Type: Grant
    Filed: September 23, 1991
    Date of Patent: October 27, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kin S. Lam, Daniel R. Schroeder, Jacqueline Mattei, James A. Matson, Salvatore Forenza
  • Patent number: 5036010
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: April 26, 1990
    Date of Patent: July 30, 1991
    Assignee: Bristol-Myers Company
    Inventors: King S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • Patent number: 5001112
    Abstract: Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.
    Type: Grant
    Filed: March 17, 1989
    Date of Patent: March 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sandra J. Hofstead, James A. Matson, Kin S. Lam, Salvatore Forenza, James A. Bush, Koji Tomita
  • Patent number: 4994271
    Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: February 16, 1988
    Date of Patent: February 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Kin S. Lam, Jacqueline Mattei, John E. Leet, James A. Matson, Koji Tomita, Murray A. Kaplan
  • Patent number: 4743594
    Abstract: Actinomadura melliaura nov. sp. (ATCC 39691) produces four novel compounds which we have designated AT 2433 A.sub.1, AT 2433 A.sub.2, AT 2433 B.sub.1 and AT 2433 B.sub.2. The novel compounds or pharmaceutically acceptable salts thereof exhibit antibacterial and antitumor activity.
    Type: Grant
    Filed: September 17, 1984
    Date of Patent: May 10, 1988
    Assignee: Schering Corporation
    Inventors: Ann C. Horan, Jerzy Golik, James A. Matson, Mahesh G. Patel
  • Patent number: 4599310
    Abstract: A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.
    Type: Grant
    Filed: September 25, 1985
    Date of Patent: July 8, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, James A. Bush
  • Patent number: 4598145
    Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
    Type: Grant
    Filed: April 16, 1984
    Date of Patent: July 1, 1986
    Assignee: Bristol-Myers Company
    Inventors: James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush